JAK Inhibition in the Treatment of Alopecia Areata

Author(s):

Arash Mostaghimi, MD, MPH,Amy McMichael, MD

Key Takeaways

Baricitinib and deuruxolitinib inhibit JAK1/2, while ritlecitinib targets JAK3 and TEC, reflecting different mechanisms of action in alopecia treatment.
Selective inhibition focuses on specific JAK pathways, potentially minimizing off-target effects and improving safety profiles.
Pan-inhibition affects multiple JAK pathways, which may enhance efficacy but also increase the risk of adverse effects.
Understanding the differences in JAK inhibitor selectivity is essential for optimizing therapeutic strategies in alopecia management.

EP: 1.Impact of Alopecia Areata on Quality of Life, and Current Standard of Treatment

EP: 2.JAK Inhibitor Baricitinib for Treatment of Alopecia Areata

EP: 3.Analyzing Phase 3 Clinical Trial Data of Baricitinib in Alopecia Areata

EP: 4.Novel Mechanisms of Action for Treatment of Alopecia Areata

EP: 5.Physician and Patient Communication for the Management of Alopecia Areata

EP: 6.The Pathophysiology of Alopecia Areata

EP: 7.The Benefits of Early Diagnosis of Alopecia Areata

EP: 8.Patient Factors and Other Considerations for Treatment Selection

EP: 9.Treatment Options for Alopecia Areata

EP: 10.Review of FDA Approved JAK Inhibitors for Alopecia Areata

Now Viewing

EP: 11.JAK Inhibition in the Treatment of Alopecia Areata

Video content above is prompted by the following:

Three JAK inhibitors are FDA-approved for the treatment of alopecia: baricitinib and deuruxolitinib (JAK1/2 inhibitors), and ritlecitinib (selective JAK3 and TEC inhibitor). Can you talk about the differences in mechanisms of action and how they might influence treatment efficacy for alopecia?

How does selective inhibition differ from pan-inhibition?